Company behind the EpiPen is caught up in another drug price scandal
You’d think one scandal would be enough.
Mylan, the company that came under fire this summer for systematically raising the price of the EpiPen, is caught up in another drug price scheme.
The pharmaceutical player is one of six companies accused of inflating prices of a diabetes drug and an antibiotic, according to the New York Times. The complaint centers on generic, rather than brand-name, drugs.
A civil complaint filed by 20 states claims that the drug companies coordinated a price-fixing scheme through personal phone calls and texts as well as “informal industry gatherings,” the Times said. Read more…More about Pharmaceuticals, Healthcare And